Please use this identifier to cite or link to this item: https://repositorio.uca.edu.ar/handle/123456789/1667
Título : Emerging drugs for autonomic dysfunction in Parkinson's disease
Autor : Pérez Lloret, Santiago 
Rey, Verónica 
Pavy-Le Traon, Anne 
Rascol, Olivier 
Palabras clave : TOXINA BOTULIMICAESTREÑIMIENTODOMPERIDONADROXIDOPADISFUNCION ERECTILFLUDROCORTISONAINCONTINENCIAHIPOTENSION ORTOSTATICAENFERMEDAD DE PARKINSONDISFUNCION URINARIA
Fecha de publicación : 2013
Editorial : Taylor and Francis
Cita : Pérez Lloret, S., et al. Emerging drugs for autonomic dysfunction in Parkinson's disease [en línea]. Preprint del documento publicado en Expert Opinion on Emerging Drugs. 2013, 18 (1). doi:10.1517/14728214.2013.766168. Disponible en: https://repositorio.uca.edu.ar/handle/123456789/1667
Resumen : Abstract: Autonomic dysfunction, including orthostatic hypotension (OH), sialorrhea, sexual dysfunction, urinary dysfunction and constipation is a common feature of Parkinson’s disease (PD). Even though its treatment has been recognized as a major unmet need in PD, there is a paucity of clinical trials to assess their treatment. Areas covered: Evidence about the efficacy and safety of available treatments for autonomic dysfunction is summarized. Potential targets for upcoming therapies are then discussed in light of what is currently known about the physiopathology of each disorder in PD. Proof-of-concept trials and circumstantial evidence about treatments for autonomic dysfunction as well as upcoming clinical trials are discussed. Finally, critical aspects of clinical trials design are considered. Expert opinion: Botulinum toxin (BTX) or glycopyrrolate might be used for sialorrhea whereas macrogol could be useful in constipation. There is preliminary evidence suggesting that fludrocortisone, domperidone, droxidopa or fipamezole may be effective for the treatment of OH. Tropicamide, clonidine or radiotherapy are under development for sialorrhea. Sildenafil may be effective for the treatment of erectile dysfunction; BTX or behavioral therapy for urinary incontinence and lubiprostone and probiotics for constipation. Sound clinical trials are needed in order to allow firm evidence-based recommendations about these treatments
URI : https://repositorio.uca.edu.ar/handle/123456789/1667
Disciplina: MEDICINA
DOI: 10.1517/14728214.2013.766168
Derechos: Acceso Abierto
Appears in Collections:Artículos

Files in This Item:
File Description SizeFormat
emerging-drugs-autonomic.pdf288,37 kBAdobe PDFThumbnail
View/Open
Show full item record

Page view(s)

87
checked on Feb 24, 2021

Download(s)

126
checked on Feb 24, 2021

Google ScholarTM

Check


Altmetric


This item is licensed under a Creative Commons License Creative Commons